Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

2.

Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol.

Gaisler-Salomon I, Weiner I.

Psychopharmacology (Berl). 2003 Apr;166(4):333-42. Epub 2003 Feb 22.

PMID:
12599023
4.

Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine.

Barak S, Weiner I.

Psychopharmacology (Berl). 2010 Apr;209(2):175-84. doi: 10.1007/s00213-010-1785-z. Epub 2010 Feb 24.

PMID:
20179909
5.

Disruption and potentiation of latent inhibition by risperidone: the latent inhibition model of atypical antipsychotic action.

Weiner I, Schiller D, Gaisler-Salomon I.

Neuropsychopharmacology. 2003 Mar;28(3):499-509. Epub 2002 Sep 23.

8.

Latent inhibition in 35-day-old rats is not an "adult" latent inhibition: implications for neurodevelopmental models of schizophrenia.

Zuckerman L, Rimmerman N, Weiner I.

Psychopharmacology (Berl). 2003 Sep;169(3-4):298-307. Epub 2003 Jun 24.

PMID:
12827344
9.

Disruption of latent inhibition in the rat by the 5-HT2 agonist DOI: effects of MDL 100,907, clozapine, risperidone and haloperidol.

Hitchcock JM, Lister S, Fischer TR, Wettstein JG.

Behav Brain Res. 1997 Oct;88(1):43-9.

PMID:
9401707
10.

Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia.

Lipina T, Labrie V, Weiner I, Roder J.

Psychopharmacology (Berl). 2005 Apr;179(1):54-67. Epub 2005 Mar 10.

PMID:
15759151
11.

Co-administration of 5-HT6 receptor antagonists with clozapine, risperidone, and a 5-HT2A receptor antagonist: effects on prepulse inhibition in rats.

Fijał K, Popik P, Nikiforuk A.

Psychopharmacology (Berl). 2014 Jan;231(1):269-81. doi: 10.1007/s00213-013-3234-2. Epub 2013 Aug 18.

14.

The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.

Weiner I.

Psychopharmacology (Berl). 2003 Sep;169(3-4):257-97. Epub 2003 Feb 25. Review.

PMID:
12601500
15.

Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat.

Black MD, Varty GB, Arad M, Barak S, De Levie A, Boulay D, Pichat P, Griebel G, Weiner I.

Psychopharmacology (Berl). 2009 Jan;202(1-3):385-96. doi: 10.1007/s00213-008-1289-2. Epub 2008 Aug 16.

PMID:
18709358
17.

Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning.

McDonald LM, Moran PM, Vythelingum GN, Joseph MH, Stephenson JD, Gray JA.

Psychopharmacology (Berl). 2003 Sep;169(3-4):321-31. Epub 2002 Aug 9.

PMID:
14530903
18.

Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia.

Barak S, Arad M, De Levie A, Black MD, Griebel G, Weiner I.

Neuropsychopharmacology. 2009 Jun;34(7):1753-63. doi: 10.1038/npp.2008.232. Epub 2009 Jan 21.

19.

The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin.

Shadach E, Gaisler I, Schiller D, Weiner I.

Neuropsychopharmacology. 2000 Aug;23(2):151-61.

20.

Supplemental Content

Support Center